e13026Background: Palbociclib was the first CDK 4/6 inhibitor approved in Argentina for HR+/HER2- advanced/ metastatic breast cancer (ABC/ MBC) in combination with letrozole or fulvestrant. However, no data exists on real world outcomes associated with palbociclib in Argentina. Ibrance Real World Insights (IRIS) is a multi-country study aimed to describe treatment patterns and clinical outcomes of patients receiving palbociclib in real world clinical practices. Methods: Medical records of adult female patients with HR+/HER2- ABC/ MBC who received palbociclib + letrozole or fulvestrant were reviewed by their treating physicians. Data on demographic and clinical characteristics, treatment patterns, and clinical outcomes were extracted. Progression free rate and survival at 6 and 12 months were estimated via Kaplan-Meier analysis. Results: 162 patient records were abstracted by 41 physicians. Approximately, 44% of physicians were from public practices. The mean (SD) age of patients at palbociclib initiation ...